Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Osteogenic sarcoma is a challenging bone cancer.
• Cell-mediated cytotoxicity plays a role in anti-tumor immunity.
• Transfer factor therapy is being explored for various conditions.

Purpose of the Study:

• To evaluate the effect of tumor-specific transfer factor on cell-mediated cytotoxicity in osteogenic sarcoma patients.
• To assess the utility of serial cytotoxicity measurements in monitoring treatment efficacy.

Main Methods:

• Serial in vitro measurements of tumor-specific cell-mediated cytotoxicity and T-cell subsets (active and total rosette-forming cells).
• Administration of osteogenic sarcoma-specific or non-specific dialyzable transfer factor to patients.
• Correlation of cytotoxicity levels with tumor burden and treatment response.

Main Results:

• Patients with large tumors had low baseline cytotoxicity, which increased after tumor-specific transfer factor administration.
• Tumor-specific transfer factor increased cell-mediated cytotoxicity in all treated patients.
• Non-specific transfer factor was associated with declining cytotoxicity.
• Clinical and histological changes (pain, edema, lymphocytic infiltrates) suggested anti-tumor response in some patients.

Conclusions:

• Tumor-specific transfer factor may enhance cell-mediated cytotoxicity against osteogenic sarcoma.
• Serial cell-mediated cytotoxicity measurements are valuable for monitoring transfer factor therapy efficacy.
• Cytotoxicity measurements can guide the selection of optimal donors for tumor-specific transfer factor.